Videos

Psychedelic Compounds Could Soon Be Billion-dollar Business for Treating Depression

David Hellerstein, MD, professor of clinical psychiatry at Columbia, has been part of a recent FDA-approved clinical study that included 233 patients with depression who were given the psychedelic psilocybin, derived from psychedelic mushrooms, as a treatment for their depression. “It looks like it has an effect, whether it's a psychological effect, like inducing a spiritual or mystical experience,” Dr. Hellerstein said. “The other hypothesis is it works on reorganizing brain networks and encouraging neurogenesis, which is development of new brain cells.”

Dr. David Hellerstein on COMPASS’s Phase IIb trial: Psilocybin Therapy for Treatment-resistant Deprsesion

Discussing the Latest Research on Psychedelics with Dr. David Hellerstein

Get Help for Chronic Depression

David J. Hellerstein, MD
Professor of Clinical Psychiatry,
Columbia University Department of Psychiatry Research Psychiatrist,
New York State Psychiatric Institute

Leading Psychiatrist and Researcher Dr. David Hellerstein from the Depression Evaluation Service of Columbia University's Department of Psychiatry explains, in an interview by TBN's Joy in Our Town, how to get your depression evaluated and treated.

Part 1

Part 2